DE
Methodology breakdown computing — it will appear here on its own.
Journey Medical Corp (DERM) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for DERM — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 46.40 | NEUTRAL |
| Stochastic %K (14) | 3.64 | BUY |
| CCI (20) | -23.67 | NEUTRAL |
| Williams %R (14) | -96.36 | BUY |
| MACD (12,26,9) | -0.04 | SELL |
| ROC (10) | -6.03 | SELL |
| Momentum (10) | -0.45 | SELL |
| EMA (10) | 7.53 | SELL |
| SMA (10) | 7.60 | SELL |
| EMA (20) | 7.37 | SELL |
| SMA (20) | 7.38 | SELL |
| EMA (30) | 7.23 | SELL |
| SMA (30) | 7.06 | BUY |
| EMA (50) | 7.02 | BUY |
| SMA (50) | 6.98 | BUY |
| EMA (100) | 6.81 | BUY |
| SMA (100) | 6.42 | BUY |
| EMA (200) | 7.08 | BUY |
| SMA (200) | 6.94 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Background via Yahoo Finance — informational, not part of the verdict.
🟢 STRONG BUY SETUP
Strong confluence across multiple layers — outperforming the market by 20.7%, RSI in healthy zone. High conviction entry. Use `!plan DERM [entry] [stop] [target]` to size the position properly.
Scores: 4 bullish / 0 bearish
Average — needs more confirmation before sizing up
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 62 |
| ⏰ 4H | RANGING | 28 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
